Faron Pharmaceuticals Oy (HEL:FARON)

Faron Pharmaceuticals Oy Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	7.61	6.93	9.05	7.51	9.88
Research & Development	12.66	11.74	19.52	20.71	17.36
Other Operating Expenses	-	-	-	-0.8	-6.14
Operating Expenses	20.27	18.67	28.57	27.43	21.11
Operating Income	-20.27	-18.67	-28.57	-27.43	-21.11
Interest Expense	-1.27	-3.94	-2.13	-1.37	-0.22
Interest & Investment Income	0.06	0.09	0.23	0.01	0
Currency Exchange Gain (Loss)	-0.11	0.07	0.01	0.04	0.16
Other Non Operating Income (Expenses)	-6.97	-3.46	-0.49	0.01	-0.02
EBT Excluding Unusual Items	-28.56	-25.92	-30.94	-28.73	-21.18
Other Unusual Items	1.31	-	-	-	-
Pretax Income	-27.26	-25.92	-30.94	-28.73	-21.18
Income Tax Expense	0	0.01	-	-	0.02
Net Income	-27.26	-25.92	-30.94	-28.73	-21.19
Net Income to Common	-27.26	-25.92	-30.94	-28.73	-21.19
Shares Outstanding (Basic)	112	89	65	55	51
Shares Outstanding (Diluted)	112	89	65	55	51
Shares Change (YoY)	26.21%	36.07%	17.79%	8.88%	10.96%
EPS (Basic)	-0.24	-0.29	-0.48	-0.52	-0.42
EPS (Diluted)	-0.24	-0.29	-0.48	-0.52	-0.42
Free Cash Flow	-17.92	-22.31	-23.81	-22.99	-22.23
Free Cash Flow Per Share	-0.16	-0.25	-0.37	-0.42	-0.44
EBITDA	-20.05	-18.47	-28.37	-27.29	-20.97
D&A For EBITDA	0.22	0.2	0.2	0.14	0.14
EBIT	-20.27	-18.67	-28.57	-27.43	-21.11

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.